• Curcumin-Piperlongumine Hybrid Targets EGFR-TKI-Resistant NS

  2026-05-26

  This study introduces a curcumin-piperlongumine hybrid (CP) as a novel therapeutic agent for EGFR-TKI-resistant non-small cell lung cancer (NSCLC), demonstrating enhanced antitumor activity through induction of cell cycle arrest and apoptosis. The combination of network pharmacology and experimental validation links CP’s efficacy to PI3K/AKT pathway modulation, highlighting new avenues for overcoming drug resistance.

• 2X HyperFusion High-Fidelity Master Mix: Precision for Cloni

  2026-05-25

  The 2X HyperFusion™ High-Fidelity Master Mix streamlines high-accuracy PCR for cloning, CRISPR editing, and immunotherapy research. Its unique enzyme fusion offers unmatched fidelity, rapid cycling, and consistent blunt-end generation—empowering researchers to achieve robust, error-minimized results in demanding translational workflows.

• Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress SASP in Ath

  2026-05-25

  This study uncovers how berberine alleviates senescence-associated secretory phenotype (SASP)–driven inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway in macrophage-derived foam cells. The mechanistic insights highlight the role of ubiquitination and transcriptional regulation in targeting chronic vascular inflammation, suggesting new directions for dissecting PPARγ signaling in age-related cardiovascular disease.

• Wortmannin: PI3K Inhibitor Workflows in Viral and Cancer Res

  2026-05-24

  Wortmannin stands apart as a selective, irreversible PI3K inhibitor, powering advanced research into both cancer signaling and viral entry mechanisms. This article offers actionable protocols, troubleshooting strategies, and cross-domain perspectives that maximize the compound’s reliability for dissecting the PI3K/Akt/mTOR pathway and related cellular processes.

• SB 431542 in Epithelial Regeneration: Precision ALK5 Inhibit

  2026-05-23

  Explore the unique role of SB 431542 as a potent ALK5 inhibitor in epithelial regeneration and cell fate engineering. This article delivers advanced mechanistic insight and practical protocols for TGF-β pathway inhibition, setting it apart from conventional cancer-focused reviews.

• Uridine, Trisodium Salt: Precision Control in RNA-Mediated G

  2026-05-22

  Explore how Uridine, Trisodium Salt enables precise, scalable RNA-mediated genome engineering as a nucleoside analog and RNA biosynthesis precursor. This article uniquely deciphers the mechanistic nuances and assay implications of using high-purity uridine in next-generation molecular biology workflows.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-05-22

  The reference study reveals how certain kinase inhibitors not only block p38α MAP kinase activity but also promote its dephosphorylation by stabilizing activation loop conformations. This dual-action mechanism offers new strategies for achieving specificity and potency in kinase inhibition, with practical implications for inflammatory disease research.

• Catalpol Mechanisms in Alzheimer's Disease: Anti-Inflammator

  2026-05-21

  This article reviews the reference study's comprehensive analysis of catalpol, an iridoid glycoside, and its multi-modal neuroprotective effects in Alzheimer's disease (AD) models. The findings emphasize catalpol's anti-inflammatory, antioxidant, and antiapoptotic actions, offering mechanistic clarity and supporting further research into metabolic and inflammatory modulation in neurodegeneration.

• T7 RNA Polymerase: Advancing RNA Synthesis for Translational

  2026-05-21

  This thought-leadership article explores how T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, is reshaping RNA synthesis for translational researchers. By blending mechanistic insight with strategic guidance, the article covers in vitro transcription enzyme selection, workflow optimization for RNA vaccine production, and lessons learned from recent mRNA vaccine efficacy studies. It uniquely positions APExBIO’s T7 RNA Polymerase (SKU K1083) as a pivotal tool, referencing the latest literature and internal expert resources to inform best practices and future directions.

• Sulfo-NHS-LC-Biotin: Practical Guide for Cell Surface Biotin

  2026-05-20

  Sulfo-NHS-LC-Biotin enables efficient, irreversible biotin labeling of primary amines on cell surface proteins in fully aqueous systems. It is specifically intended for workflows requiring covalent, membrane-impermeable modification, and should not be used for intracellular or reversible biotinylation. This guide outlines protocol parameters and actionable best practices for reliable application.

• Patient-Derived Gastric Cancer Assembloid Model: A New Bench

  2026-05-20

  This study introduces a patient-derived gastric cancer assembloid that integrates matched tumor organoids with autologous stromal subpopulations, closely recapitulating the primary tumor microenvironment. The model provides a powerful platform to dissect tumor–stroma interactions, investigate drug response variability, and enable more predictive personalized therapeutic strategies.

• Thiothixene: Typical Antipsychotic Agent & Efferocytosis Mod

  2026-05-19

  Thiothixene is a typical antipsychotic agent with dual actions: central dopamine D2/serotonin 5-HT2A antagonism and unique enhancement of in vitro macrophage efferocytosis. Its pharmacokinetics, safety, and workflow parameters are well characterized, supporting both neuropsychiatric and immunological research.

• RG7388 MDM2 Antagonist: Applied Workflows and Troubleshootin

  2026-05-19

  RG7388, a second-generation oral MDM2 antagonist, delivers potent, selective p53 pathway activation and robust cancer cell apoptosis induction in wild-type p53 models. This guide translates recent mechanistic insights and preclinical benchmarks into practical experimental workflows and troubleshooting strategies for oncology research.

• Bestatin-Mediated Dissection of Jasmonate Signaling in Arabi

  2026-05-18

  The reference study demonstrates that bestatin, an aminopeptidase inhibitor, serves as a precise chemical probe to dissect jasmonate (JA) signaling in Arabidopsis. By leveraging chemical genetics and mutant screening, the research uncovers new loci involved in JA-mediated defense and developmental pathways, providing a robust experimental platform for plant signal transduction research.

• KPT330 Enhances CRISPR-Cas9 Precision by Modulating mRNA Exp

  2026-05-18

  The referenced study uncovers a novel mechanism by which the FDA-approved drug KPT330 enhances the specificity of CRISPR-Cas9 genome and base editing via selective regulation of Cas9 mRNA nuclear export. This discovery establishes small-molecule export inhibitors as a new class of indirect CRISPR modulators, offering a promising strategy to mitigate off-target effects in genome editing applications.

407 records 14/28 page Previous Next First page 上5页 1112131415 下5页 Last page